The headline sounds like clickbait, but the numbers backing it up are real. Your out-of-pocket maximum for Medicare Part D prescriptions is jumping to $2,100 in 2026—a 5% increase from 2025’s $2,000 limit—and that’s only part of the problem. For a retiree taking multiple medications for chronic conditions, this creeping increase compounds every year. If you’re managing diabetes, heart disease, and high cholesterol with three prescription medications, you’re now looking at hitting that $2,100 ceiling faster than last year, even before factoring in the deductible you’ll pay first. The worse-than-you-think part isn’t just the rising caps.
It’s the interaction of higher deductibles, higher out-of-pocket maximums, and the fact that many Medicare beneficiaries don’t understand how these costs stack up. Your maximum deductible is now $615 in 2026, up from $590 in 2025. After you meet that deductible, you pay 25% coinsurance for both generic and brand-name drugs—meaning you’re still responsible for a quarter of each prescription’s cost until you hit the $2,100 out-of-pocket maximum. For a 70-year-old taking Eliquis for atrial fibrillation at roughly $180 per month, that’s $45 per month out of your pocket in coinsurance alone, even before reaching catastrophic coverage. There is some relief coming through drug price negotiations, but those savings are concentrated on 10 specific medications, and not all of them may be what you’re taking.
Table of Contents
- How Much Are Your Deductibles and Out-of-Pocket Costs Really Going Up?
- The Coverage Gap That Was Eliminated—But There’s Still No Free Lunch
- What You’re Actually Paying Each Month for Part D Coverage
- The Drug Price Negotiations That Are Real But Limited in Scope
- The Medicare Prescription Payment Plan and Its Hidden Advantage
- What’s Coming in 2027—Ozempic and 14 More Medications
- The Bigger Picture—Why These Costs Matter Now and Later
- Conclusion
How Much Are Your Deductibles and Out-of-Pocket Costs Really Going Up?
The $2,100 out-of-pocket maximum represents a 5% year-over-year increase, which may sound modest until you realize this is the third consecutive year of increases. Over three years, the cap has grown from approximately $2,000 in 2024 to $2,100 in 2026—a steady upward march that outpaces general inflation. The deductible increase is smaller in percentage terms—from $590 to $615, just a 4.2% bump—but every dollar matters when you’re living on a fixed retirement income. Here’s where it gets difficult: these cost increases aren’t happening evenly across all beneficiaries. some Part D plans still offer zero-deductible options, but those plans typically charge higher monthly premiums or restrict your drug choices.
If you choose a plan with the maximum $615 deductible to save on premiums, you’ll pay that full amount before your insurance covers any prescriptions. Then, once your deductible is met, you pay 25% coinsurance on medications until you reach the $2,100 out-of-pocket limit. A generic blood pressure medication that costs $30 monthly means you’re paying $7.50 in coinsurance per prescription. A brand-name diabetes medication at $200 monthly means $50 out-of-pocket. The math accelerates quickly with multiple medications. For context, if you’re taking a typical combination of prescriptions for someone over 65—say, a statin, a blood pressure medication, and a diabetes drug—you could easily spend $500 to $800 annually in out-of-pocket costs just to reach that deductible and initial coinsurance phase, before you ever touch the $2,100 maximum.
The Coverage Gap That Was Eliminated—But There’s Still No Free Lunch
One genuinely good change from 2025 forward is that the “donut hole” or coverage gap has been completely eliminated. Under the old system, beneficiaries would hit a coverage gap between initial coverage and catastrophic coverage, where they paid a much higher percentage of drug costs. Now, there are only three phases: you pay your deductible, then 25% coinsurance, and once you hit $2,100 in out-of-pocket spending, you move directly to catastrophic coverage where you pay only a small copay for the rest of the year. This simplification sounds better than it is. The elimination of the donut hole removes a confusing and expensive surprise, but it doesn’t lower the overall cost ceiling.
You still need to spend $2,100 out-of-pocket before reaching catastrophic coverage. What the change does is eliminate the worst-of-both-worlds scenario where you paid significantly higher percentages in the gap. The limitation here is that many retirees still believe the donut hole exists and are bracing for a non-existent cost cliff, which at least saves them from the mental shock—but they’re often unprepared for the actual cumulative costs leading up to that $2,100 threshold. The practical warning: if you’re managing multiple chronic conditions with expensive medications, you’ll likely reach catastrophic coverage before the calendar year ends. That sounds like a good thing—and it is, once you’re there—but it also means you’ll pay $2,100 out-of-pocket in a single calendar year for prescriptions, which is a significant annual expenditure on a fixed income.
What You’re Actually Paying Each Month for Part D Coverage
The average standalone Part D plan costs $34.50 per month in 2026, down $3.81 from 2025. If you have a Medicare Advantage plan with integrated Part D coverage, you’re looking at an average of $11.50 per month, down $1.82 from 2025. These are national averages, and your actual premium will vary based on which specific plan you choose, where you live, and what your plan covers. Plans in rural areas or with narrower formularies may cost less or more depending on the drug costs in your region. Here’s where the math gets tricky: those declining premiums are actually a rare piece of good news for 2026, but they’re declining from already-elevated levels.
You’re still paying $34.50 monthly for a standalone plan, which adds up to $414 per year just for the insurance premium—before you pay a single prescription copay, coinsurance, or meet your deductible. For someone taking multiple medications, this premium is just the entry fee. It’s a limitation worth noting: lower premiums often come with higher deductibles or more restrictive drug formularies. Many beneficiaries choose a cheaper plan thinking they’re saving money, only to discover that their preferred medications are on a higher cost tier or simply aren’t covered. A practical comparison: a beneficiary choosing a standalone Part D plan at $34.50 monthly plus a $615 deductible is committed to spending at least $1,029 in the first year on Part D alone ($414 in premiums plus $615 deductible) before they receive any actual medication coverage. This is before a single prescription hits the pharmacy counter.
The Drug Price Negotiations That Are Real But Limited in Scope
For the first time, Medicare has used its negotiating power to reduce prices on specific drugs. In 2026, ten medications have negotiated prices, saving an estimated $6 billion across all beneficiaries and delivering an average of 38-79% discounts off 2023 list prices. The medications include Eliquis (for blood clots), Jardiance (for diabetes), and Xarelto (for blood clots), plus seven others treating cancer, heart failure, autoimmune conditions, and chronic kidney disease. The savings sound substantial, and they are for the people taking these specific drugs. Nearly 9 million beneficiaries are expected to save $1.5 billion in out-of-pocket costs in 2026 from these price negotiations. However, this is where you need to understand the limitation: these are ten drugs out of thousands available through Part D.
If your prescriptions aren’t among these ten, you receive no benefit from the negotiation program. Additionally, the savings represent discounts off the 2023 list prices, not necessarily the lowest possible prices. Pharmaceutical manufacturers can still adjust their strategies around the negotiated prices. Some may raise prices on other formulations of similar drugs or adjust their marketing and patient assistance programs in response. The real value depends on whether you take one of these ten drugs. For someone taking Jardiance for type 2 diabetes—a medication prescribed to millions of Americans—the negotiated price could mean several hundred dollars in annual savings. For someone taking an older, off-brand antidepressant or arthritis medication, the negotiation program offers nothing.
The Medicare Prescription Payment Plan and Its Hidden Advantage
Most Medicare beneficiaries don’t know about the Medicare Prescription Payment Plan (MPPP), which allows you to spread monthly out-of-pocket drug costs rather than paying large, unexpected amounts at the pharmacy. This is particularly valuable during the first several months of the year when you’re meeting your deductible and coinsurance obligations. Instead of facing a $200 bill for medications in January, an $180 bill in February, and another $220 in March, the MPPP lets you average your costs across twelve months. Here’s the important change for 2027: beneficiaries who enroll in the MPPP in 2026 will be automatically re-enrolled for 2027 unless they actively opt out.
This removes a friction point—you won’t have to re-enroll and won’t accidentally miss enrollment. The limitation, however, is that many Part D plans and pharmacies still don’t widely promote this program, and some beneficiaries aren’t aware it exists until they’ve already paid large out-of-pocket amounts. Additionally, not all pharmacies accept MPPP arrangements, so you need to confirm with your pharmacy before assuming you can spread your costs. A warning worth noting: the MPPP doesn’t reduce your total out-of-pocket costs; it only spreads them across the year. You’ll still hit your $2,100 maximum eventually, but you won’t face the same month-to-month payment shock that can derail budgets for retirees on fixed incomes.
What’s Coming in 2027—Ozempic and 14 More Medications
Looking ahead to 2027, Medicare will add 15 more medications to the price negotiation program, including Ozempic (for type 2 diabetes), which has become wildly expensive and is prescribed to millions of Americans. This represents a nearly doubling of the scope of negotiated prices, from 10 drugs to 25 drugs by 2027. The expansion signals that the negotiation program is gaining traction and will likely include additional medications in subsequent years.
However, similar limitations apply: if you’re not taking one of these 25 drugs, you still benefit only from whatever savings the market offers independently. Also, pharmaceutical manufacturers have adjusted their behavior in response to negotiations. Some have aggressively marketed alternative drugs not yet subject to negotiation, or they’ve raised prices on non-negotiated formulations to offset their losses on negotiated products.
The Bigger Picture—Why These Costs Matter Now and Later
The 2026 changes represent a pattern that will continue: steady increases in deductibles and out-of-pocket maximums, offset partially by government interventions like drug price negotiations and programs like the MPPP. The good news is that Congress is actively working to reduce medication costs for Medicare beneficiaries. The bad news is that the current system still shifts significant costs to retirees, and those costs are rising every year.
For future planning, understand that your Part D costs in 2026 are likely not your Part D costs in 2030. These numbers will increase. If you’re currently age 62 and planning to enroll in Medicare at 65, assume that the out-of-pocket maximums will be higher, deductibles will be higher, and your medications may or may not benefit from price negotiations. The one variable you can control is choosing the right plan and understanding your coverage before you need it, rather than after you’re surprised by large bills.
Conclusion
The numbers behind “worse than you think” are simple: you’re paying more for the privilege of buying prescriptions, even with recent relief measures. The $2,100 out-of-pocket maximum, the $615 deductible, and the 25% coinsurance obligations create a real cost burden for Americans managing chronic diseases on fixed retirement incomes. Yes, drug price negotiations are helping nearly 9 million beneficiaries save $1.5 billion, and yes, the donut hole is gone.
But these improvements are targeted and incremental, not systemic. To protect yourself in 2026, review your Part D plan during open enrollment, understand whether you’re taking one of the ten drugs subject to price negotiations, and consider whether the MPPP could reduce the month-to-month stress of medication costs. Compare plans based on total annual cost—not just premiums—and account for your actual medications, not hypothetical ones. The numbers won’t get better on their own, but informed planning can keep them from getting worse.